[FUS[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX-- Protein (Fused In Sarcoma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a multifunctional RNA- and DNA-binding protein encoded by the FUS gene on chromosome 16p11.2. It is a 526-amino acid nuclear protein that plays critical roles in RNA metabolism, including transcription, splicing, RNA transport, and DNA repair 1(. Mutations in FUS are causative for approximately 4–5% of familial [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- (ALS) cases and are also linked to [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (FTD), establishing FUS as a key protein in the ALS-FTD disease spectrum 2(https://www.nature.com/articles/s41591-021-01615-z). FUS belongs to the FET protein family (FUS, EWSR1, TAF15), all of which contain similar domain architectures and have been implicated in [neurodegeneration[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases 3(](https://link.springer.com/article/10.1186/s13024-025-00851-y). [2]
¶ Protein Structure and Domains
FUS has a modular domain architecture consisting of several functional regions 4(https://pmc.ncbi.nlm.nih.gov/articles/PMC10997494/):
¶ Low-Complexity Domain (LCD)
The N-terminal low-complexity domain (residues 1–165) is enriched in glutamine, glycine, serine, and tyrosine residues. This prion-like domain is critical for:
- Liquid-liquid phase separation (LLPS): The LCD drives the formation of membraneless organelles and biomolecular condensates
- Self-assembly: The purified LCD forms liquid-like droplets that can mature into gel-like hydrogels composed of amyloid-like polymers
- Transcriptional activation: Interacts with RNA polymerase II and transcription factors
Unlike pathogenic amyloid fibrils, FUS LCD polymers are normally labile and can disassemble upon dilution, reflecting their dynamic, reversible nature 5(https://www.pnas.org/doi/10.1073/pnas.2114412118).
The central RRM domain (residues 285–371) mediates sequence-specific RNA binding and contributes to:
- Pre-mRNA splicing regulation
- mRNA stability and localization
- MicroRNA processing
¶ RGG Domains
Three arginine-glycine-glycine-rich (RGG1, RGG2, RGG3) domains flank the RRM and zinc finger domains. These regions:
- Enhance RNA binding through electrostatic interactions
- Are targets for arginine methylation, which modulates phase separation behavior
- Contribute to nuclear-cytoplasmic shuttling
¶ Zinc Finger Domain (ZnF)
A zinc finger domain (residues 422–453) provides additional nucleic acid binding capacity and cooperates with the RRM for RNA recognition.
The C-terminal PY-NLS (residues 510–526) is recognized by the nuclear import receptor Transportin-1 (TNPO1), which mediates nuclear import and also suppresses aberrant cytoplasmic phase transitions 6(https://www.jbc.org/article/S0021-9258(21)00447-6/fulltext).
FUS is an abundant nuclear protein that regulates nearly every level of RNA processing 3(https://link.springer.com/article/10.1186/s13024-025-00851-y):
- Transcription: Associates with RNA polymerase II and promoter regions; regulates expression of thousands of [genes[/[genes[/[genes[/[genes[/[genes[/[genes[/[genes[/genes
- Splicing: Controls alternative splicing of hundreds of pre-mRNA targets, including those encoding synaptic proteins
- Polyadenylation: Regulates 3' end processing of mRNAs
- RNA transport: Facilitates transport of mRNAs to neuronal dendrites and axons for local translation
- MicroRNA biogenesis: Participates in [microRNA] processing pathways
FUS is rapidly recruited to sites of DNA damage, where it:
¶ Phase Separation and Biomolecular Condensates
FUS undergoes liquid-liquid phase separation to form dynamic, membraneless compartments including:
- Paraspeckles: Nuclear bodies involved in gene regulation
- Stress granules: Cytoplasmic RNA-protein granules formed during cellular stress
- DNA damage foci: Sites of DNA repair
- Transport granules: Neuronal RNA granules for mRNA localization
Mutations in FUS cause familial ALS with distinctive features 2(https://www.nature.com/articles/s41591-021-01615-z):
Clinical Features:
- Younger onset: Typically second to fourth decade of life, with some juvenile-onset cases
- Aggressive course: Survival often limited to 6 months to 3 years after symptom onset
- Lower motor neuron predominance: Progressive weakness, atrophy, and fasciculations
- Bulbar involvement: Dysarthria and dysphagia common
- Cognitive changes: Some patients develop features of FTD
Key Pathogenic Mutations:
- P525L: Located in the NLS; causes severe cytoplasmic mislocalization; associated with aggressive juvenile-onset ALS 8(https://www.neurology.org/doi/10.1212/NXG.0000000000200009)
- R521C/G/H: Cluster of mutations in the NLS region; variable age of onset
- R495X: Truncation mutation removing the NLS entirely
- G156E: Within the LCD; alters phase separation dynamics
Pathological Features:
- Cytoplasmic FUS-positive inclusions in motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and glial cells
- Nuclear depletion of FUS protein
- Basophilic inclusions characteristic of FUS-ALS
- Absence of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology (distinguishing FUS-ALS from typical ALS)
FUS pathology defines a subset of FTLD cases (FTLD-FUS) 3(https://link.springer.com/article/10.1186/s13024-025-00851-y):
- Atypical FTLD-U: FUS-positive, [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX---negative inclusions
- Basophilic inclusion body disease (BIBD): FUS-positive basophilic inclusions
- Neuronal intermediate filament inclusion disease (NIFID): FUS co-localizes with neurofilament inclusions
ALS-associated mutations, particularly those affecting the NLS, disrupt [Transportin-1]-mediated nuclear import, leading to cytoplasmic accumulation of FUS. Once in the cytoplasm, FUS:
- Incorporates into [stress granules[/mechanisms/[stress-granules[/mechanisms/[stress-granules[/mechanisms/[stress-granules--TEMP--/mechanisms)--FIX--
- Undergoes aberrant phase transitions from liquid to solid states
- Forms irreversible amyloid-like aggregates 5(https://www.pnas.org/doi/10.1073/pnas.2114412118)
Cytoplasmic FUS aggregates exert toxicity through:
- Sequestration of essential RNA-binding proteins and mRNAs
- Disruption of local translation at synapses
- Impairment of [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- and [protein quality control]
- Interference with [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- and function
- Activation of [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- via [microglia[/entities/microglia/https://www.eurekalert.org/news-releases/[1048251[/entities/microglia/https://www.eurekalert.org/news-releases/[1048251[/entities/microglia/https://www.eurekalert.org/news-releases/[1048251--TEMP--/entities/microglia/https://www.eurekalert.org)--FIX--.
Jacifusen (ION363) is an antisense oligonucleotide targeting FUS mRNA to reduce FUS protein levels 10(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00513-6/abstract):
- Delivered via intrathecal injection
- Reduces FUS protein in cerebrospinal fluid by >90%
- In patients with the P525L mutation, mutant FUS protein levels were reduced to 3–4% of untreated controls
- An open-label case series reported encouraging results in slowing disease progression
- Phase trials ongoing as of 2025
The HSP40 co-chaperone DNAJB6 has been identified as a potent suppressor of FUS toxicity 11(https://www.nature.com/articles/s41467-025-65178-0):
- Maintains FUS in a loose gel-like state, preventing fibrilization
- Rescues toxicity from multiple ALS/FTD-associated RNA-binding proteins
- Represents a potential therapeutic target for broad-spectrum [neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection--TEMP--/treatments)--FIX--
- Compounds that stabilize FUS in its liquid phase and prevent solidification
- Nuclear import enhancers that restore FUS nuclear localization
- Inhibitors of post-translational modifications that promote aggregation
FUS shares functional and pathological overlap with several other proteins implicated in neurodegeneration:
- [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--: Both are RNA-binding proteins with prion-like domains; together they define the major ALS-FTD proteinopathies, though their pathologies rarely co-occur
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX--: Hexanucleotide repeat expansions produce dipeptide repeats that can sequester FUS and disrupt its function
- [SOD1/proteins/sod1: Another ALS-causing protein; SOD1-ALS and FUS-ALS show distinct pathological signatures
- EWSR1 and TAF15: Fellow FET family members that co-aggregate with FUS in FTLD-FUS cases
- Transportin-1 (TNPO1): Nuclear import receptor that chaperones FUS; mutations disrupting this interaction drive disease
The study of Fus Protein (Fused In Sarcoma) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [/mechanisms/app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing[/mechanisms/[app-processing--TEMP--/mechanisms)--FIX--
- [/mechanisms/amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation[/mechanisms/[amyloid-aggregation--TEMP--/mechanisms)--FIX--
- [/mechanisms/microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--
- [/entities/trem2[/entities/[trem2[/entities/[trem2[/entities/[trem2--TEMP--/entities)--FIX--
- [/mechanisms/mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--
- Mackenzie IR, et al. FUS pathology in Motor [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- Disease and frontotemporal lobar degeneration. Acta Neuropathol. 2010;120(1):1-3. DOI:10.1007/s00401-010-0699-5
- Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX--. Cell. 2009;136(6):1001-1004. DOI:10.1016/j.cell.2009.03.014
- Dormann D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010;29(16):2841-2857. DOI:10.1038/emboj.2010.143
- Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208-1211. DOI:10.1126/science.1165942
- Kwiatkowski TJ, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205-1208. DOI:10.1126/science.1166066## See Also
-
- Shneider NA et al., Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series (2025)
- Ge R et al., DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases (2025)
- Zetterberg H et al., Review: Fluid biomarkers for frontotemporal dementias (2019)
- Magrath Guimet N, Zapata-Restrepo LM, Miller BL, Advances in Treatment of Frontotemporal Dementia (2022)
- Mustafin RN, Role of Retroelements in Frontotemporal Dementia Development (2025)
- Panza F et al., Development of disease-modifying drugs for Frontotemporal Dementia spectrum disorders (2020)
- Ho WY et al., Dysfunction in nonsense-mediated decay, protein homeostasis, mitochondrial function, and brain connectivity in ALS-FUS mice with cognitive deficits (2021)
- Gao FB, et al. FUS-linked ALS: emerging mechanisms and therapeutic targets. Nat Rev Neurol. 2021;17(12):705-718. DOI:10.1038/s41582-021-00554-0
- Suzuki N, et al. FUS mutations in ALS: mechanisms of disease and therapeutic implications. Mol Neurodegener. 2022;17(1):77. DOI:10.1186/s13024-022-00571-7
- Kim HJ, et al. FUS pathology in cellular and animal models of ALS/FTD. Acta Neuropathol Commun. 2023;11(1):10. DOI:10.1186/s40478-023-01524-x